Skip to ContentSkip to Navigation
About usNews and EventsNews articles

Influenza vaccination in primary and secondary immunodeficiencies

21 September 2011

PhD ceremony: Mr. S. van Assen, 16.15 uur, Aula Academiegebouw, Broerstraat 5, Groningen

Dissertation: Influenza vaccination in primary and secondary immunodeficiencies

Promotor(s): prof. C.G.M. Kallenberg

Faculty: Medical Sciences

 

Patients with immunodeficiencies are at increased risk of contracting common and/or opportunistic infections, that might be prevented or mitigated by vaccination. We investigated the humoral and cell-mediated immune (CMI) responses following influenza vaccination in patients with humoral primary immunodeficiencies (hPID), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)-patients treated with rituximab. In patients with hPID humoral responses following influenza vaccination were clearly hampered. Previous vaccination and treatment with intravenous immunoglobulin did not result in higher seroprotection rates. Antibody responses were also decreased in SLE-patients. A second influenza vaccination four weeks later only led to an additional increase in the influenza-specific antibody responses in not previously vaccinated SLE-patients. Influenza vaccination within four to eight weeks after administration of rituximab did not result in a humoral response in rituximab-induced B-cell depleted RA-patients. Six to 10 months following rituximab therapy an antibody response was found although it was still hampered. CMI responses following influenza vaccination were impaired in the hPID, SLE and rituximab-treated RA-patients. In SLE-patients reduced CMI responses were associated with the use of prednisone and/or azathioprine. In conclusion, the patients with primary and secondary immunodeficiencies we investigated demonstrated hampered humoral and CMI responses following influenza vaccination. We developed evidence- and expert-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases for the European League Against Rheumatism (EULAR).

 

Last modified:15 September 2017 3.40 p.m.

More news

  • 23 April 2019

    From paperclip to patent

    How is it possible that an albatross doesn’t crash and die when it lands? And how come its large wings don’t break due to air resistance? That is what you would expect, according to the laws of aerodynamics. However, Professor Eize Stamhuis has discovered...

  • 16 April 2019

    A thorough characterization of structural variants in human genomes

    Human genomes vary quite a bit from individual to individual. These differences include single nucleotide changes, or “spelling mistakes” in the DNA sequence, but even more variation comes from structural variants, which include additions, deletions...

  • 02 April 2019

    ‘Sense of loss drives voting behaviour’

    ‘Everybody here loves that academia has returned to Friesland. We teach, carry out research and think along about solutions to problems that are relevant for Friesland,’ says Caspar van den Berg, Professor of Global and Local Governance at the UG Campus...